Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

In UC, Skyrizi faces direct competition from Eli Lilly’s IL-23 inhibitor Omvoh (mirikizumab), approved by the FDA last year, although that isn’t yet approved for Crohn’s disease. The IBD ...

After hours: 7 March at 7:59:57 pm GMT-5 Loading Chart for LLY ...

The Royal Enfield Bullet 350 holds a special place in the segment due to its retro design, rich heritage, and reliability. The Bullet 350 is built on an all-new chassis to contain RE's new J ...

Found the MG TF of your dreams? Now you want to know all about it! With the help of Parkers, you can find out all of the key specs about the MG TF from fuel efficiency in MPG and top speed in MPH, to ...

Keep up with the latest news in business & general aviation and specific featured experts on Wednesday’s AirMail Focus It is our mission to be the go-to leaders in the aviation industry. GlobalAir.com ...